Zydus Pharmaceuticals (USA) Inc is the US generic drug division of a much larger, India-based company known as Zydus Cadila Healthcare. Zydus Cadila is a global, fully integrated pharmaceutical company with a presence in 50 countries and is committed to growing its presence around the world and in the United States.
Zydus Cadila has been achieving this goal both through acquisitions and organic growth. Globally, over the last 6 years, it has acquired companies in France, Japan, Brazil, Spain, and South Africa. There is also acquisition activity occurring within the United States. Throughout the world, Zydus is focused on providing outstanding customer service, along with high-quality, affordable products. Its vision is to be a leading global health care provider with a robust pipeline and sales over $3 billion by 2015.
While Zydus Cadila continues to focus on the domestic market in India, it is growing rapidly in key regulated global generic markets, such as the United States, Europe, and Latin America. As the 4th largest pharmaceutical company in India, Zydus is well positioned to meet the needs of today’s generic pharmaceutical marketplace and is forging relationships as a strategic contract manufacturer. What sets the company apart is a never-ending commitment to innovation and building a strong product pipeline, with a focus on products that will deliver the most value to the company as well as customers.
Zydus Cadila takes pride in its manufacturing and development history, which spans more than 50 years. Its FDAapproved Moraiya plant is India’s largest finished dosage plant under one roof, with a total space of 40 acres. Its modular design allows for rapid expansion to add capacity and meet the ever-growing global demand for generic pharmaceutical products. The breadth of the company’s product form capability—tablets, hard and soft gelatin capsules, parenterals, metered dose inhalers, and transdermal patches—sets it up to be “The Global Sourcing Partner of Choice” in the generic pharmaceutical industry.
Three technology centers—the Zydus Research Center, the Pharmaceutical Technology Center, and Active Pharmaceutical Ingredient (API) Process Research—all work together to develop the best quality products now and for the future. Zydus is also one of India’s largest API manufacturers, with 2 of its facilities FDA-approved and supporting many of its generic formulations.
Chief Executive Officer of the US division, Joe Renner, envisions a US generic marketplace where manufacturers and customers come together in the sourcing of generic products earlier on in the continuum of product management, in order to maximize the risk–reward profiles and deliver maximum value to all parties involved. With major support from its parent company, Zydus Pharmaceuticals (USA) Inc. continues to grow by delivering products to the US marketplace. To date, the company has filed 91 drug master files, received 67 Abbreviated New Drug Application (ANDA) final and tentative approvals, and has 46 ANDAs pending approval with the FDA.
With now over 223 SKUs commercially available, Zydus continues to grow within the US marketplace. In fact, Zydus, for the 6th straight year, has been named by IMS Health as one of the fastest-growing pharmaceutical companies. IMS Health also listed Zydus in the top 20 (#12) US Generic Companies based upon total prescriptions dispensed.
Zydus’ success to date is predicated upon its outstanding customer service, expanding generic portfolio, and dedication to being vertically integrated on many finished dosage forms. Its very strong US management team has more than 100 years of combined experience in the US generic marketplace.
Recent company achievements include: reaching $1 billion in revenue worldwide, along with the launches of potassium chloride 10mEq ER tabs and generic venlafaxine XR, bioequivalent to Pfizer’s Effexor XR.® You can visit Zydus at their booth (location number 1120) or learn more about Zydus Pharmaceuticals through their Web site, www.zydususa.com.
Zydus is poised to continue its tremendous growth, with its low-cost production, R&D/legal/regulatory capabilities for product development, and, most importantly, customer focus. Clearly, Zydus Cadila and its worldwide divisions are setting themselves up to be known as “The Global Sourcing Partner of Choice.” PT
For more information, visit www.zydususa.com.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs